{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:24:46Z","timestamp":1793838286259,"version":"4.6.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most antibodies for treating COVID-19 rely on binding the receptor-binding domain (RBD) of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). However, Omicron and its sub-lineages, as well as other heavily mutated variants, have rendered many neutralizing antibodies ineffective. Here we show that antibodies with enhanced resistance to the evolution of SARS-CoV-2 can be identified via deep mutational learning. We constructed a library of full-length RBDs of Omicron BA.1 with high mutational distance and screened it for binding to the angiotensin-converting-enzyme-2 receptor and to neutralizing antibodies. After deep-sequencing the library, we used the data to train ensemble deep-learning models for the prediction of the binding and escape of a panel of eight therapeutic antibody candidates targeting a diverse range of RBD epitopes. By using in silico evolution to assess antibody breadth via the prediction of the binding and escape of the antibodies to millions of Omicron sequences, we found combinations of two antibodies with enhanced and complementary resistance to viral evolution. Deep learning may enable the development of therapeutic antibodies that remain effective against future SARS-CoV-2 variants.<\/jats:p>","DOI":"10.1038\/s41551-025-01353-4","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:04:11Z","timestamp":1741151051000},"page":"552-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Deep mutational learning for the selection of therapeutic antibodies resistant to the evolution of Omicron variants of SARS-CoV-2"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1689-3068","authenticated-orcid":false,"given":"Lester","family":"Frei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-6595","authenticated-orcid":false,"given":"Beichen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-1885","authenticated-orcid":false,"given":"Jiami","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1345-6122","authenticated-orcid":false,"given":"Joseph M.","family":"Taft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8185-6454","authenticated-orcid":false,"given":"Edward B.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-8996","authenticated-orcid":false,"given":"C\u00e9dric R.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-403X","authenticated-orcid":false,"given":"Rachita K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5568-8179","authenticated-orcid":false,"given":"Benedikt N.","family":"Eisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-8748","authenticated-orcid":false,"given":"Andrey","family":"Ignatov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9177-0857","authenticated-orcid":false,"given":"Sai T.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"1353_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf1906","volume":"13","author":"BE Jones","year":"2021","unstructured":"Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. 13, eabf1906 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1353_CR2","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"1353_CR3","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384\u20132393.e12 (2021).","journal-title":"Cell"},{"key":"1353_CR4","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.abl8506","volume":"374","author":"M McCallum","year":"2021","unstructured":"McCallum, M. et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science 374, 1621\u20131626 (2021).","journal-title":"Science"},{"key":"1353_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2021","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2021).","journal-title":"Nature"},{"key":"1353_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2381","volume":"32","author":"LB Shrestha","year":"2022","unstructured":"Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N. & Bull, R. A. Evolution of the SARS\u2010CoV\u20102 Omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev. Med. Virol. 32, e2381 (2022).","journal-title":"Rev. Med. Virol."},{"key":"1353_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"1353_CR8","doi-asserted-by":"publisher","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).","journal-title":"Cell Rep."},{"key":"1353_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1473-3099(22)00733-2","volume":"23","author":"P Arora","year":"2023","unstructured":"Arora, P. et al. Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. Lancet Infect. Dis. 23, 22\u201323 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1353_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","volume":"608","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608, 603\u2013608 (2022).","journal-title":"Nature"},{"key":"1353_CR11","unstructured":"COVID-19 Vaccines for People Who Are Moderately or Severely Immunocompromised (Centers for Disease Control and Prevention, 2023); https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html?s_cid=10483:immunocompromised%20and%20covid%20vaccine:sem.ga:p:RG:GM:gen:PTN:FY21 ."},{"key":"1353_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYB Lee","year":"2022","unstructured":"Lee, A. R. Y. B. et al. Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis. Brit. Med. J. 376, e068632 (2022).","journal-title":"Brit. Med. J."},{"key":"1353_CR13","doi-asserted-by":"publisher","first-page":"1108546","DOI":"10.3389\/fpubh.2023.1108546","volume":"11","author":"S Martinelli","year":"2023","unstructured":"Martinelli, S., Pascucci, D. & Laurenti, P. Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review. Front. Public Health 11, 1108546 (2023).","journal-title":"Front. Public Health"},{"key":"1353_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168603","volume":"133","author":"A Casadevall","year":"2023","unstructured":"Casadevall, A. & Focosi, D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. J. Clin. Invest. 133, e168603 (2023).","journal-title":"J. Clin. Invest."},{"key":"1353_CR15","unstructured":"Considerations for Implementing and Adjusting Public Health and Social Measures in the Context of COVID-19 (World Health Organization, 2023) https:\/\/www.who.int\/publications\/i\/item\/who-2019-ncov-adjusting-ph-measures-2023.1"},{"key":"1353_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.1616408114","volume":"114","author":"T Jain","year":"2017","unstructured":"Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944\u2013949 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1353_CR17","first-page":"1","volume":"13","author":"B Zhou","year":"2022","unstructured":"Zhou, B. et al. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Nat. Commun. 13, 1\u201314 (2022).","journal-title":"Nat. Commun."},{"key":"1353_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tips.2021.11.010","volume":"43","author":"KR Hanning","year":"2022","unstructured":"Hanning, K. R., Minot, M., Warrender, A. K., Kelton, W. & Reddy, S. T. Deep mutational scanning for therapeutic antibody engineering. Trends Pharmacol. Sci. 43, 123\u2013135 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"1353_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295\u20131310.e20 (2020).","journal-title":"Cell"},{"key":"1353_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41586-021-03807-6","volume":"597","author":"TN Starr","year":"2021","unstructured":"Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97\u2013102 (2021).","journal-title":"Nature"},{"key":"1353_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.abf9302","volume":"371","author":"TN Starr","year":"2021","unstructured":"Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850\u2013854 (2021).","journal-title":"Science"},{"key":"1353_CR22","doi-asserted-by":"publisher","first-page":"100255","DOI":"10.1016\/j.xcrm.2021.100255","volume":"2","author":"TN Starr","year":"2021","unstructured":"Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. Med. 2, 100255 (2021).","journal-title":"Cell Rep. Med."},{"key":"1353_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24435-8","volume":"12","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat. Commun. 12, 4196 (2021).","journal-title":"Nat. Commun."},{"key":"1353_CR24","doi-asserted-by":"publisher","first-page":"109627","DOI":"10.1016\/j.celrep.2021.109627","volume":"36","author":"IM Francino-Urdaniz","year":"2021","unstructured":"Francino-Urdaniz, I. M. et al. One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening. Cell Rep. 36, 109627 (2021).","journal-title":"Cell Rep."},{"key":"1353_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-02656-9","author":"E Callaway","year":"2023","unstructured":"Callaway, E. Why a highly mutated coronavirus variant has scientists on alert. Nature https:\/\/doi.org\/10.1038\/d41586-023-02656-9 (2023).","journal-title":"Nature"},{"key":"1353_CR26","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/S1473-3099(23)00573-X","volume":"23","author":"S Yang","year":"2023","unstructured":"Yang, S. et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 23, e457\u2013e459 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1353_CR27","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/S1473-3099(23)00575-3","volume":"23","author":"K Uriu","year":"2023","unstructured":"Uriu, K. et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect. Dis. 23, e460\u2013e461 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1353_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veac021","volume":"8","author":"AJ Greaney","year":"2022","unstructured":"Greaney, A. J., Starr, T. N. & Bloom, J. D. An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain. Virus Evol. 8, veac021 (2022).","journal-title":"Virus Evol."},{"key":"1353_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010160","volume":"18","author":"EK Makowski","year":"2022","unstructured":"Makowski, E. K., Schardt, J. S., Smith, M. D. & Tessier, P. M. Mutational analysis of SARS-CoV-2 variants of concern reveals key tradeoffs between receptor affinity and antibody escape. PLoS Comput. Biol. 18, e1010160 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"1353_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39199-6","volume":"14","author":"W Han","year":"2023","unstructured":"Han, W. et al. Predicting the antigenic evolution of SARS-COV-2 with deep learning. Nat. Commun. 14, 3478 (2023).","journal-title":"Nat. Commun."},{"key":"1353_CR31","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41591-023-02483-5","volume":"29","author":"G Wang","year":"2023","unstructured":"Wang, G. et al. Deep-learning-enabled protein\u2013protein interaction analysis for prediction of SARS-CoV-2 infectivity and variant evolution. Nat. Med. 29, 2007\u20132018 (2023).","journal-title":"Nat. Med."},{"key":"1353_CR32","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1016\/j.cell.2022.08.024","volume":"185","author":"JM Taft","year":"2022","unstructured":"Taft, J. M. et al. Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. Cell 185, 4008\u20134022.e14 (2022).","journal-title":"Cell"},{"key":"1353_CR33","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1371\/journal.pone.0003647","volume":"3","author":"C Engler","year":"2008","unstructured":"Engler, C., Kandzia, R. & Marillonnet, S. A one pot, one step, precision cloning method with high throughput capability. PLoS ONE 3, e3647 (2008).","journal-title":"PLoS ONE"},{"key":"1353_CR34","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1021\/acssynbio.1c00525","volume":"11","author":"JM Pryor","year":"2022","unstructured":"Pryor, J. M., Potapov, V., Bilotti, K., Pokhrel, N. & Lohman, G. J. S. Rapid 40\u2009kb genome construction from 52 parts through data-optimized assembly design. ACS Synth. Biol. 11, 2036\u20132042 (2022).","journal-title":"ACS Synth. Biol."},{"key":"1353_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky1182","volume":"47","author":"GM Taylor","year":"2019","unstructured":"Taylor, G. M., Mordaka, P. M. & Heap, J. T. Start-Stop Assembly: a functionally scarless DNA assembly system optimized for metabolic engineering. Nucleic Acids Res. 47, e17 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1353_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005553","volume":"4","author":"C Engler","year":"2009","unstructured":"Engler, C., Gruetzner, R., Kandzia, R. & Marillonnet, S. Golden gate shuffling: a one-pot DNA shuffling method based on type IIs restriction enzymes. PLoS ONE 4, e5553 (2009).","journal-title":"PLoS ONE"},{"key":"1353_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nbt0697-553","volume":"15","author":"ET Boder","year":"1997","unstructured":"Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553\u2013557 (1997).","journal-title":"Nat. Biotechnol."},{"key":"1353_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261045","volume":"17","author":"PL Tzou","year":"2022","unstructured":"Tzou, P. L., Tao, K., Kosakovsky Pond, S. L. & Shafer, R. W. Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS ONE 17, e0261045 (2022).","journal-title":"PLoS ONE"},{"key":"1353_CR39","doi-asserted-by":"publisher","first-page":"100991","DOI":"10.1016\/j.xcrm.2023.100991","volume":"4","author":"Q He","year":"2023","unstructured":"He, Q. et al. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. Cell Rep. Med. 4, 100991 (2023).","journal-title":"Cell Rep. Med."},{"key":"1353_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1353_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1766","volume":"373","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science 373, eabh1766 (2021).","journal-title":"Science"},{"key":"1353_CR42","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"1353_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"1353_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450\u2013456 (2020).","journal-title":"Nature"},{"key":"1353_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41586-021-03817-4","volume":"597","author":"MA Tortorici","year":"2021","unstructured":"Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103\u2013108 (2021).","journal-title":"Nature"},{"key":"1353_CR46","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.abf4830","volume":"371","author":"CG Rappazzo","year":"2021","unstructured":"Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823\u2013829 (2021).","journal-title":"Science"},{"key":"1353_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34506-z","volume":"13","author":"A Moulana","year":"2022","unstructured":"Moulana, A. et al. Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1. Nat. Commun. 13, 7011 (2022).","journal-title":"Nat. Commun."},{"key":"1353_CR48","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"1353_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2022","unstructured":"Cox, M. et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 21, 112\u2013124 (2022).","journal-title":"Nat. Rev. Microbiol."},{"key":"1353_CR50","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41587-021-01179-w","volume":"40","author":"ML Bileschi","year":"2022","unstructured":"Bileschi, M. L. et al. Using deep learning to annotate the protein universe. Nat. Biotechnol. 40, 932\u2013937 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1353_CR51","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S1473-3099(22)00524-2","volume":"22","author":"DJ Sheward","year":"2022","unstructured":"Sheward, D. J. et al. Evasion of neutralising antibodies by omicron sublineage BA.2.75. Lancet Infect. Dis. 22, 1421\u20131422 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1353_CR52","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286.e8 (2023).","journal-title":"Cell"},{"key":"1353_CR53","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.chom.2022.09.002","volume":"30","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host Microbe 30, 1512\u20131517.e4 (2022).","journal-title":"Cell Host Microbe"},{"key":"1353_CR54","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1110\/ps.0306603","volume":"12","author":"MM Meyer","year":"2003","unstructured":"Meyer, M. M. et al. Library analysis of SCHEMA-guided protein recombination. Protein Sci. 12, 1686\u20131693 (2003).","journal-title":"Protein Sci."},{"key":"1353_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28307-7","volume":"13","author":"J Dufloo","year":"2022","unstructured":"Dufloo, J. et al. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. Nat. Commun. 13, 1\u201311 (2022).","journal-title":"Nat. Commun."},{"key":"1353_CR56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2104651118","volume":"118","author":"M Meijers","year":"2021","unstructured":"Meijers, M., Vanshylla, K., Gruell, H., Klein, F. & L\u00e4ssig, M. Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody. Proc. Natl Acad. Sci. USA 118, e2104651118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1353_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-03665-3","volume":"9","author":"MB Doud","year":"2018","unstructured":"Doud, M. B., Lee, J. M. & Bloom, J. D. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat. Commun. 9, 1\u201312 (2018).","journal-title":"Nat. Commun."},{"key":"1353_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104475","volume":"89","author":"AP Underwood","year":"2023","unstructured":"Underwood, A. P. et al. Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and\/or COVID-19 vaccination. EBioMedicine 89, 104475 (2023).","journal-title":"EBioMedicine"},{"key":"1353_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abp8328","volume":"7","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Sci. Immunol. 7, eabp8328 (2022).","journal-title":"Sci. Immunol."},{"key":"1353_CR60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.abh2315","volume":"374","author":"KM Hastie","year":"2021","unstructured":"Hastie, K. M. et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science 374, 472\u2013478 (2021).","journal-title":"Science"},{"key":"1353_CR61","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"1353_CR62","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/bioinformatics\/btaa739","volume":"37","author":"MIJ Raybould","year":"2021","unstructured":"Raybould, M. I. J., Kovaltsuk, A., Marks, C. & Deane, C. M. CoV-AbDab: the coronavirus antibody database. Bioinformatics 37, 734\u2013735 (2021).","journal-title":"Bioinformatics"},{"key":"1353_CR63","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S1473-3099(23)00010-5","volume":"23","author":"C Yue","year":"2023","unstructured":"Yue, C. et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect. Dis. 23, 278\u2013280 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1353_CR64","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/s41559-023-02123-8","volume":"7","author":"W Ma","year":"2023","unstructured":"Ma, W., Fu, H., Jian, F., Cao, Y. & Li, M. Immune evasion and ACE2 binding affinity contribute to SARS-CoV-2 evolution. Nat. Ecol. Evol. 7, 1457\u20131466 (2023).","journal-title":"Nat. Ecol. Evol."},{"key":"1353_CR65","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1353_CR66","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cell.2023.02.001","volume":"186","author":"B Dadonaite","year":"2023","unstructured":"Dadonaite, B. et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike. Cell 186, 1263\u20131278.e20 (2023).","journal-title":"Cell"},{"key":"1353_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/protein\/gzq002","volume":"23","author":"L Benatuil","year":"2010","unstructured":"Benatuil, L., Perez, J. M., Belk, J. & Hsieh, C.-M. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng. Des. Sel. 23, 155\u2013159 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"1353_CR68","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.cell.2022.06.023","volume":"185","author":"L Li","year":"2022","unstructured":"Li, L. et al. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell 185, 2952\u20132960.e10 (2022).","journal-title":"Cell"},{"key":"1353_CR69","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/jcc.27025","volume":"44","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern. J. Comput. Chem. 44, 594\u2013601 (2023).","journal-title":"J. Comput. Chem."},{"key":"1353_CR70","unstructured":"BBMap. SourceForge (2022); https:\/\/sourceforge.net\/projects\/bbmap\/"},{"key":"1353_CR71","unstructured":"Van Rossum, G. & Drake, F. L., Jr. The Python Language Reference Manual (Network Theory, 2011)."},{"key":"1353_CR72","doi-asserted-by":"publisher","first-page":"W281","DOI":"10.1093\/nar\/gks469","volume":"40","author":"MCF Thomsen","year":"2012","unstructured":"Thomsen, M. C. F. & Nielsen, M. Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion. Nucleic Acids Res. 40, W281\u2013W287 (2012).","journal-title":"Nucleic Acids Res."},{"key":"1353_CR73","doi-asserted-by":"publisher","unstructured":"Gao, B. & Frei, L. Deep learning-guided selection of antibody therapies with enhanced resistance to current and prospective SARS-CoV-2 Omicron variants. Zenodo https:\/\/doi.org\/10.1101\/2023.10.09.561492 (2024).","DOI":"10.1101\/2023.10.09.561492"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01353-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01353-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01353-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T18:03:21Z","timestamp":1744826601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01353-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01353-4","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.R.W. is an employee of Alloy Therapeutics (Switzerland). C.R.W. and S.T.R. hold shares of Alloy Therapeutics. S.T.R. is on the scientific advisory board of Alloy Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}